PET Opposition to Discretionary Denial Brief | Dec 26, 2025 | PAPER | PETITIONER |
USP11103552 | Dec 26, 2025 | EXHIBIT | PETITIONER |
EO | Dec 26, 2025 | EXHIBIT | PETITIONER |
WH Fact Sheet | Dec 26, 2025 | EXHIBIT | PETITIONER |
Alvotech Press Release | Dec 26, 2025 | EXHIBIT | PETITIONER |
FDA Press Release | Dec 26, 2025 | EXHIBIT | PETITIONER |
Teva/Alvotech Press Release | Dec 26, 2025 | EXHIBIT | PETITIONER |
Regeneron's Preliminary Patent Owner Response (PGR2025-00085) | Dec 26, 2025 | PAPER | PATENT OWNER |
Public Trial Transcript Excerpts, Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 22-cv-61 (N.D.W. Va.) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Wang, Protein Aggregation and Its Inhibition in Biopharmaceutics, 289 Int. J. Pharm. 1 (2005) (“Wang 2005”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Wang, Instability, Stabilization, and Formulation of Liquid Protein Pharmaceuticals, 1856 Int. J. Pharm. 129 (1999) (“Wang 1999”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Philip J. Rosenfeld et al., Maximum Tolerated Dose of a Humanized Anti-Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration, 112 Ophthalmology 1048 (2005) (“Rosenfeld 2005”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
U.S. Patent Application Publication No. 2004/0197324 (“Liu 2004”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
U.S. Patent No. 7,087,411 (“Daly”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
WO 2006/138181 (”Gokarn”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Rahul N. Khurana et al., Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular AgeRelated Macular Degeneration, 128 Ophthalmology 1027 (2021) (“Khurana 2021”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
James A. Dixon et al., VEGF Trap-Eye for the Treatment of Neovascular Age-Related Macular Degeneration, 18 Expert Opinion Investigational Drugs 1573 (2009) (“Dixon 2009”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Pravin U. Dugel et al., HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration, 128 Ophthalmology 89 (2021) (“Dugel”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
John S.Y. Park & David R. Chow, Clinical Primer on Eylea HD: Review of the Current Data, Retina Specialist (Apr. 13, 2024), https://www.retina-specialist.com/article/clinical-primer-oneylea-hd-review-of-the-current-data (“Park”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Vabysmo Label 2024 (“Vabysmo Label”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Jonas L. Fast et al., Physical Instability of a Therapeutic Fc Fusion Protein: Domain Contributions to Conformational and Colloidal Stability, 48 Biochemistry 11724 (2009) (“Fast”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Zaltrap Label 2023 (“Zaltrap Label”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Michael Thomas, Comparative Effectiveness of Aflibercept for the Treatment of Patients with Neovascular Age-related Macular Degeneration, 7 Clinical Ophthalmology 495 (2013) (“Thomas”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Alvotech, Report of Foreign Private Issuer (Form 6-K) (June 23, 2025) (“Alvotech Press Release”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Molecular Partners, Molecular Partners to Regain Global Rights to Abicipar, Molecular Partners News Release Details (Aug. 8, 2021) https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-regain-globalrights-abicipar (“Molecular Partners Press Release”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Novartis, Novartis Reports One Year Results of Phase III MERLIN Study Evaluating Beovu® Every Four Week Dosing and Provides Update on Beovu Clinical Program, Novartis Media Releases (May 28, 2021) https://www.novartis.com/news/mediareleases/novartis-reports-one-year-results-phase-iii-merlin-studyevaluating-beovu-every-four-week-dosing-and-provides-updatebeovu-clinical-program (“Novartis Press Release”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
U.S. Patent Application Publication No. 2023/0416353 | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
WO 2014/009465 | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
U.S. Food & Drug Admin., Eylea HD Approval Letter (Aug. 18, 2018) (“Eylea HD FDA Approval Letter”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Gerard A. Rodrigues, Functional Characterization of AbiciparPegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability, 59 Investigative Ophthalmology & Visual Science 5836 (2018) (“Rodrigues 2018”) | Dec 26, 2025 | EXHIBIT | PATENT OWNER |
Patent Owner's Discretionary Denial Brief | Nov 26, 2025 | PAPER | PATENT OWNER |
Excerpts from the File History of U.S. Appl. No. 17/384,070 | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
US 2018/0326126 (“Fiedler ’126”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Australian Dep’t of Health & Human Aging, Australian Public Assessment Report for Aflibercept (July 2012) (“AusPAR”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Ameya U. Borwankar et al., Viscosity Reduction of a Concentrated Monoclonal Antibody with Arginine.HCl and Arginine.Glutamate, 55 Ind. Eng. Chem. Rsch. 11225 (2016) (“Borwankar”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Neal Whitaker et al., A Formulation Development Approach to Identify and Select Stable Ultra–High-Concentration Monoclonal Antibody Formulations with Reduced Viscosities, 106 J. Pharmaceutical Scis. 3230 (2017) (“Whitaker”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Ameya U. Borwankar et al., Viscosity Reduction of a Concentrated Monoclonal Antibody with Arginine.HCl and Arginine.Glutamate: Supplementary Information, 55 Ind. Eng. Chem. Rsch. 11225 (2016) (“Borwankar SI”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Eylea HD® Highlights of Prescribing Information (Oct. 2024) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
AbbVie, Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar Pegol, AbbVie News Center (June 26, 2020), https://news.abbvie.com/2020-06-26-Allerganan-AbbVie-Company-and-Molecular-Partners-ReceiveComplete-Response-Letter-from-FDA-on-Biologics-LicenseApplication-for-Abicipar-pegol (“AbbVie PR”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Rod McNeil, Advances and Developments in Medical Retina, 25 Eye News 1 (2019) (“McNeil”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Rehan M. Hussain & Thomas A. Ciulla, Emerging Vascular Endothelial Growth Factor Antagonists to Treat Neovascular Age-Related Macular Degeneration, 22 Expert Op. Emerging Drugs 235 (2017) (“Hussain”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Angus Liu, Novartis Calls off 3 Beovu Trials Testing More Frequent Dosing on Concerns of Vision-Threatening Side Effect, FiercePharma (June 1, 2021) (“Liu”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Beovu Label (2024) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Philip J. Rosenfeld & David J. Browning, Editorial: Is This a 737 Max Moment for Brolucizumab?, 216 Am. J. Ophthalmology A7 (2020) (“Rosenfeld”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
J. Gaudreault et al., Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) After a Single Intravitreal Administration, 46 Invest. Ophthalmol Vis. Sci. 726 (2005) (“Gaudreault”) | Nov 26, 2025 | EXHIBIT | PATENT OWNER |
Notice: Power of Attorney | Oct 8, 2025 | PAPER | PATENT OWNER |
Notice: Mandatory Notice | Oct 8, 2025 | PAPER | PATENT OWNER |
Notice: NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE | Sep 26, 2025 | PAPER | BOARD |
US Patent No. 12168036 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Excerpts from the Prosecution History of the 036 patent Part 1 of 8 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Excerpts from the Prosecution History of the 036 patent Part 2 of 8 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Excerpts from the Prosecution History of the 036 patent Part 3 of 8 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Excerpts from the Prosecution History of the 036 patent Part 4 of 8 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Excerpts from the Prosecution History of the 036 patent Part 5 of 8 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Excerpts from the Prosecution History of the 036 patent Part 6 of 8 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Excerpts from the Prosecution History of the 036 patent Part 7 of 8 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Excerpts from the Prosecution History of the 036 patent Part 8 of 8 | Sep 17, 2025 | EXHIBIT | PETITIONER |
US Patent 7,608,261 (Furfine) | Sep 17, 2025 | EXHIBIT | PETITIONER |
US Patent 8,921,316 (Dix) | Sep 17, 2025 | EXHIBIT | PETITIONER |
US Publication 2016/0144025 A1 (Vitti) | Sep 17, 2025 | EXHIBIT | PETITIONER |
Eylea Clinical Review, Center for Drug Evaluation and Research | Sep 17, 2025 | EXHIBIT | PETITIONER |
AU Eylea Label | Sep 17, 2025 | EXHIBIT | PETITIONER |
US Publication 2015/0071920 A1 (Larson) | Sep 17, 2025 | EXHIBIT | PETITIONER |
US Publication 2017/0232199 A1 (Fiedler) | Sep 17, 2025 | EXHIBIT | PETITIONER |
WO 2016/154288 to Ingber et al. | Sep 17, 2025 | EXHIBIT | PETITIONER |
PTE Application US Patent 7374758, (App 11/016,503) | Sep 17, 2025 | EXHIBIT | PETITIONER |
Avery 2014 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Awwad 2017 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Brown 2015 | Sep 17, 2025 | EXHIBIT | PETITIONER |
CATT 2011 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Celik 2015 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Cohen 2016 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Das 2015 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Dear 2017 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Duh 2017 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Elwes 2018 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Falavarjani 2013 | Sep 17, 2025 | EXHIBIT | PETITIONER |
He 2011 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Ho 2014 - HARBOR | Sep 17, 2025 | EXHIBIT | PETITIONER |
Hong 2018 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Inoue 2014 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Jin 2017 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Lehman Brothers Presentation 2009 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Miller 2017 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Narasimhan 2012 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Neergaard 2013 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Nguyen 2009 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Nguyen 2012 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Gutierrez and Ferrara 2023 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Salinas 2010 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Stewart 2012 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Sun 2012 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Trichonas 2013 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Varma 2014 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Viswanath 2007 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Wang 2015 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Wykoff Feb 2018 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Macugen 2011 Label | Sep 17, 2025 | EXHIBIT | PETITIONER |
Beovu 2019 Label | Sep 17, 2025 | EXHIBIT | PETITIONER |
Eylea 2011 Label | Sep 17, 2025 | EXHIBIT | PETITIONER |
Eylea 2012 Label | Sep 17, 2025 | EXHIBIT | PETITIONER |
Eylea 2014 Label | Sep 17, 2025 | EXHIBIT | PETITIONER |
Eylea 2016 Label | Sep 17, 2025 | EXHIBIT | PETITIONER |
Eylea HD 2024 Label | Sep 17, 2025 | EXHIBIT | PETITIONER |
Lucentis 2017 Label | Sep 17, 2025 | EXHIBIT | PETITIONER |
Vabysmo 2022 Label | Sep 17, 2025 | EXHIBIT | PETITIONER |
Assessment Report, Eylea aflibercept | Sep 17, 2025 | EXHIBIT | PETITIONER |
Eylea Pharmacology Review | Sep 17, 2025 | EXHIBIT | PETITIONER |
EMA Annex I, Summary of Product Characteristics | Sep 17, 2025 | EXHIBIT | PETITIONER |
Loureiro 2017 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Ferrara 2010 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Channa 2011 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Rhoades 2017 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Wang 2021 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Declaration of Dr. Donald Joseph D'Amico | Sep 17, 2025 | EXHIBIT | PETITIONER |
Declaration of Dr. Robert J. Falconer | Sep 17, 2025 | EXHIBIT | PETITIONER |
Notice: Power of Attorney | Sep 17, 2025 | PAPER | PETITIONER |
Clinical Study Protocol NCT04126317 | Sep 17, 2025 | EXHIBIT | PETITIONER |
Petition: as filed | Sep 17, 2025 | PAPER | PETITIONER |
Declaration of June Anne Munford | Sep 17, 2025 | EXHIBIT | PETITIONER |